AAIC 2022

Cogstate Scientific Involvement, Meeting Opportunities, and Remote Cognitive Testing.

Cogstate is honored to be a part of the program at the 2022 Alzheimer’s Association International Conference (AAIC) in San Diego. The sharing of knowledge at these pivotal events is vital to help advance dementia science to better support the millions of individuals, families, and communities impacted by Alzheimer’s disease.

We invite those attending the conference to come to our scientific presentations, stop by our booth, and/or reach out to book a meeting with our team! For those who can’t make it in-person, please don’t hesitate to reach out to learn more about our services or book a meeting outside of AAIC.

Meet with Cogstate at AAIC | Try Remote Cognitive Testing

Cogstate’s team will be available during the duration of the event for meetings, coffee discussions, or quick chats. Whatever suits your schedule!

Stop By Booth #1006

Be sure to swing by Cogstate’s booth to chat, to grab a fun promo item, and to demo some of our digital cognitive assessments that have been optimized for remote and self-administration. Our team will be available to discuss both traditional and decentralized clinical trial services for CNS-related studies.

Book a Meeting

We’d like to meet with you during the event. Cogstate has arranged an exclusive business suite on the exhibit floor just steps away from the presentations and posters. Please reach out to your Cogstate contacts to book a meeting during the event or submit this form and our team will reach out to make arrangements.

Cogstate Scientific Presentations at AAIC

For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions, and the clinical care needs of physicians and patients around the world, with particular emphasis and experience in Alzheimer’s Disease. At this year’s AAIC event, our expertise and technology are part of 5 oral presentations and 18 posters.

Featured Presentations

TitleFormatDate/Time
Plasma pTau181/Aβ42 identifies cognitive change earlier than CSF pTau181/Ab42Oral Presentation #64341Sun, Jul 31
9:45am - 9:55am
Detection of Mild Cognitive Impairment Using In-clinic and Remote Unsupervised Digital Cognitive AssessmentsPoster #63091Mon, Aug 01
Validity of a remote supervised preclinical Alzheimer’s disease cognitive composite (PACC) score in preclinical and prodromal Alzheimer’s diseasePoster #68363Sun, Jul 31
User-led Design of a Self-administered Smartphone-based Learning and Memory AssessmentPoster #66067Tue, Aug 02
Rater perspectives on Applied Training of cognitive Clinical Outcome Assessment (COA) scales delivered by neuropsychology expertsPosterWed, Aug 03

Additional Presentations

TitleFormatDate/Time
Machine-learning based MRI neuro-anatomical signatures associated with cardiovascular and metabolic risk factorsOral PresentationSat, Jul 30
Modifiable dementia risk factors are associated with greater subjective cognitive concerns but not perceived susceptibility to dementia in late middle-aged adults: Baseline characteristics of the BetterBrains TrialPoster #64011Sun, Jul 31
Longitudinal basal forebrain atrophy in association with amyloid-β positivity and dementia severityPoster #64027Sun, Jul 31
Participant characteristics, modifiable dementia risk, and associated goal setting within a large online, multi-domain, risk factor management program (BetterBrains) to delay cognitive declinePoster #64408Sun, Jul 31
Head-to-head comparison of plasma biomarkers across the AD continuum in an Australian populationPoster #65323Sun, Jul 31
Cognitive function and hearing loss: A longitudinal investigation of the effect of hearing aid use on cognitive performance in older adultsPoster #65434Sun, Jul 31
Contribution of modifiable dementia risk factors to cognitive performance and subjective cognition in middle-aged adultsOral Presentation #66469 Sun, Jul 31
The Reliability and Validity of the Snellen Memory Test for Point-of-Care Detection of Alzheimer’s Risk in Cognitively Unimpaired Older AdultsPoster #67993Sun, Jul 31
Relationship of APOE genotypes and level of cognitive reserve to cognitive trajectories among cognitively normal individualsPoster #68284Sun, Jul 31
Establishing a Preclinical Alzheimer’s Disease Cognitive Composite (PACC) for International Combined Cohorts to Assess the Natural Progression of Alzheimer’s DiseasePoster #64338Mon, Aug 01
Machine-learning based MRI neuro-anatomical signatures associated with cardiovascular and metabolic risk factorsPoster #61530Tue, Aug 02
Modifiable dementia risk factors associated with higher CSF tau and poorer cognition in middle-aged adultsPoster #66458Tue, Aug 02
Fluctuations in reaction time performance as a marker of incipient amyloid-related cognitive decline in clinically unimpaired older adults.Lightning PresentationTue, Aug 02
Participant experience in a longitudinal online research registry: Associations between ethnocultural identity, educational attainment, and participant feedback in the Brain Health RegistryPoster #61333Wed, Aug 03
Alzheimer’s disease specific MRI brain regions are differentially associated with accelerated decline as defined using sigmoidal cognitive turning point methodology in amyloid-positive AIBL participantsPoster #64503Wed, Aug 03
Development of harmonized and co-calibrated scores for memory, executive functioning, language, and visuospatial in the AIBL Study, ADNI, and NACC datasetsPoster #64534Wed, Aug 03
Leukocyte Surface Biomarkers Implicate Deficits of Innate Immunity in Late-onset Alzheimer’s DiseaseOral Presentation #65030 Wed, Aug 03
Understanding the impact of PET amyloid cutpoints on prognostic modelling for cognitively normal individualsPoster #67418Wed, Aug 03
Objectively measured physical activity and cognition in cognitively normal older adults: A longitudinal analysis of the Australian Imaging Biomarkers and Lifestyle (AIBL) studyOral Presentation #64392Thu, Aug 04

 

Cogstate Experts Involved in Presentations

Paul Maruff, PhD

Paul Maruff, PhD

Chief Innovation Officer

Professor Paul Maruff is one of the founders of Cogstate. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioural and cognitive dysfunction. Paul’s research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods.

Chris Edgar, PhD

Chris Edgar, PhD

Chief Science Officer

Dr. Edgar is an experienced leader in cognitive assessment and clinical endpoint strategy who provides expert guidance to Cogstate’s pharmaceutical customers throughout all stages of trial conduct, from study design and test selection through final analysis. Dr. Edgar is also a key advisor to Cogstate’s commercial and product teams for the development of new technologies.

Svenja Wacker, PhD

Svenja Wacker, PhD

Science Director, Business Development

Svenja Wacker, PhD is a bilingual (German/English), licensed clinical neuropsychologist with expertise in global clinical trial management and consultation, as well as extensive experience in hospital-based rehabilitation neuropsychology, neuropsychological assessment and intervention, program development, and medical staff training. She serves as Science Director on Cogstate’s Business Development team.

Eric Siemers, MD

Eric Siemers, MD

Cogstate SAB Chair and Distinguished Medical Adviser

Dr. Siemers’ experience in clinical trials of neurodegenerative disease spans over 25 years, with a research focus on the use of biomarkers in investigational drug research, the development of trial designs that fully characterize the effects of investigational drugs on chronic diseases, and more specifically, the development of strategies for treating individuals before the onset of symptoms of neurodegenerative diseases.

View the full AAIC 2022 conference program here

How can we help you optimize the measurement of brain health?

Please fill out the form to get in touch